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Death receptors in cervical cancer
 
Death-prone T cells might increase the risk of developing cervical cancer, 
according to a study on page 967. Sun and colleagues show that
women with cervical cancer are more likely to have T cells that are 
genetically programmed to express high levels of the death-inducing 
molecule FAS ligand (FASL).
Most cervical cancers are associated with human papillomavirus 
(HPV) infection. But not all HPV-infected women develop cervical cancer, 
suggesting that other factors contribute to cancer progression. A recent 
study linked cervical cancer with a genetic polymorphism in the gene 
encoding the death receptor FAS, which triggers apoptosis when bound 
by its ligand FASL. However, these findings are controversial as other 
studies failed to confirm this association.
T cells homozygous for the  844C FASL poly-
morphism express more FASL when activated.
 
Sun and colleagues now find that a naturally occurring polymorphism in the 
 
FASL
 
 promoter was 
three times more prevalent in Chinese women with cervical cancer than in cancer-free controls. T 
cells with this single nucleotide polymorphism (
 
 
 
844C) expressed more FASL and were more prone 
to cell death after stimulation with cervical cancer cells than T cells without the polymorphism 
(
 
 
 
844T). Although the mechanism remains obscure, the authors suggest that an increased 
propensity for cell death might limit the ability of tumor-specific T cells to eradicate tumor cells.
The 
 
 
 
844C polymorphism was recently found to improve the binding of a transcription factor 
that helps drive 
 
FASL
 
 gene expression, and to increase FASL protein levels on fibroblasts. In that 
study, the polymorphism was linked to the autoimmune disease systemic lupus erythematosus (SLE). 
The link to SLE was postulated to result from increased FAS-mediated cell death, which might 
facilitate the release of nuclear antigens that are then targeted by the immune response. 
 
NK cells get helpful
 
On page 941, Mailliard et al. show that natural killer (NK) cells exposed
to the cytokine interleukin (IL)-18 commit to a life of helping rather than
killing. According to the study, IL-18 creates interferon (IFN)-
 
 
 
–producing,
T helper (Th)-1–promoting NK cells, whereas IL-2 spawns killers.
NK cells are innate immune cells known for their ability to kill trans-
formed or infected cells and to secrete cytokines including IFN-
 
 
 
. Recently,
these cells have been shown to influence the adaptive immune response by
interacting with dendritic cells (DCs), thereby triggering either DC matura-
tion or death. But the signals that determine whether NK cells kill DCs or
help them mature are not completely understood. Also unknown is whether
functionally specialized subsets of NK cells exist or whether individual NK
cells are capable of different functions depending on the circumstances.
Mailliard and colleagues now show that IL-18 and IL-2 induce distinct
pathways of human NK cell differentiation. IL-18 induced the expression of
the chemokine receptor CCR7 on NK cells and the production of IFN-
 
 
 
,
without affecting the ability of the NK cells to kill target cells. IL-2, on the
IL-18–conditioned NK cells (yellow) migrate to the 
T cell (blue) zones of lymph nodes.
 
other hand, increased NK cell killing activity but did not induce the expression of CCR7. Inter-
actions between IL-18–conditioned NK cells and DCs increased IFN-
 
 
 
 production by the NK cells
and IL-12 production by the DCs, both cytokines that promote Th1 responses.
The authors propose that IL-18–conditioned NK cells would be well suited to migrate to draining
lymph nodes after activation in vivo, as lymph node entry depends on CCR7 expression. Once
there, these cells might help amplify Th1 responses by interacting with DCs. By contrast, IL-2–
conditioned NK cells, which killed DCs in vitro, are more likely to terminate the immune response
by eliminating antigen-expressing DCs once the adaptive immune response has done its job. 
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TIM-2 soaks up ferritin
 
The TIM (T cell immunoglobulin mucin) 
proteins have emerged as key regulators 
of allergic and autoimmune diseases due 
to their influence on T helper (Th)-1 and 
Th-2 responses. On page 955, Chen
and colleagues show that one member 
of this family, TIM-2, multitasks as a 
receptor for H-ferritin, a component of 
the iron storage protein ferritin.
Ferritin was not what the group 
expected to find when they launched a 
search for TIM-2 ligands. “Ferritin is not 
something immunologists think about much,” says senior author 
William Seaman. Although circulating H-ferritin had been shown to 
increase during inflammation and to bind to T and B cells, the 
consequences of these observations were largely unknown.
Chen et al. now show that although TIM-2 is most highly 
expressed in the liver, the primary iron storage organ, this protein is 
also found on splenic B cells. TIM-2 expression was particularly high 
on germinal center B cells that were actively responding to antigenic 
stimulation. Using a TIM-2 reporter cell line, they showed that a 
soluble product of activated macrophages bound to TIM-2. That 
product was H-ferritin. Binding triggered endocytosis of the 
receptor–ligand pair, suggesting that the interaction was functional.
The authors are now investigating the consequences of the ferritin–
TIM-2 interaction. A recent study showed that intracellular H-ferritin is 
required for the antiapoptotic effect of NF-
 
 
 
B activation in fibroblasts, 
prompting Seaman to speculate that H-ferritin uptake in activated 
germinal center B cells might have a similar antiapoptotic effect. 
H-ferritin (red) binds to 
TIM-2 (green) and triggers 
endocytosis of the receptor–
ligand pair (yellow).
 
NKT cells reject islets
 
Reporting on page 913, Yasunami and colleagues
show that activation of natural killer T (NKT) cells trig-
gers rejection of transplanted insulin-producing islet
cells in mice. These data suggest a possible way to avoid
the early loss of islet cells that has stymied an otherwise
promising diabetes treatment.
Insulin-dependent diabetes is caused by destruction
of the insulin-producing cells in the pancreas by CD4
 
 
 
T cells. Transplantation of islet cells is an effective way
to restore insulin production, but this therapy requires
life-long immunosuppression of the patient. And even
with immunosuppression, up to half of the transplanted
islet cells are rapidly rejected.
Early islet rejection is associated with the production
of inflammatory cytokines such as interferon-
 
 
 
 (IFN-
 
 
 
),
but the cell types involved in IFN-
 
 
 
 production and in is-
let cell rejection had not been defined. Yasunami and col-
leagues now place the blame on NKT cells. NKT cells in
mice produced IFN-
 
 
 
 in response to islet cell transplan-
tation. This triggered the production of more IFN-
 
 
 
 by
graft-infiltrating neutrophils. In the absence of NKT cells,
neutrophils or IFN-
 
 
 
, the islet cells survived.
Multiple injections with the NKT cell–activating
compound 
 
 
 
-galactosylceramide also protected against
islet rejection, consistent with recent reports suggesting
that chronic stimulation of NKT cells decreases IFN-
 
 
 
production. Thus, early inhibition of NKT cells might
help protect transplanted islet cells, even before destruc-
tive T cells are activated. 
 
Cytokine-robbing cells
 
these cells. Rather, the immune depletion freed up activating 
cytokines, such as interleukin-7 and -15, which were being 
consumed by endogenous cells. Thus, supplementing tumor-
specific T cell transfers with activating cytokines might improve 
upon this revolutionary antitumor therapy. 
Tumor-specific T cells become fully activated in the presence 
of interleukin (IL)-7 (green dots) and IL-15 (orange diamonds).
 
Transferring tumor-specific T cells is not enough to fight disease, 
according to Gattinoni et al. on page 907, because endogenous 
cells steal necessary activating cytokines. This limits the ability of 
the transferred cells to launch an antitumor attack in mice.
Elimination of the body’s lymphocytes followed by infusion of 
tumor-specific CD8
 
 
 
 T cells has recently been shown to help 
destroy established tumors in humans. Studies in mice have 
suggested that irradiation works in two ways. The depletion of 
host cells creates empty space, which the transferred cells can fill 
by homeostatic proliferation. The depletion also rids the host of 
regulatory T (T reg) cells, which would otherwise dampen the 
function of the transferred antitumor cells.
Gattinoni and colleagues now add a new wrinkle to this story. 
They confirmed that tumor-specific T cells combated aggressive skin 
tumors more effectively in irradiated mice than in nonirradiated 
controls. To the authors’ surprise, the antitumor T cells increased to 
equivalent numbers in both mice. The cells transferred into the depleted 
mice, however, became more activated and secreted more cytokines.
The increased activation was not due to depletion of T reg 
cells, as irradiation boosted antitumor responses in mice lacking 
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